✓ Age from 18 to 80 years

✓ Some type of cancer confirmed by pathology and staged in stage III and IV.

✓ Patients who want to participate and who have no difficulty to comply with the development of the study.

✓ Must have a Karnosfsky index > 50%.

✓ Life expectancy is greater than 6 months.

✓ Minimum 4 weeks must have elapsed between the end of the last chemotherapy, radiotherapy, glucocorticoid therapy or alternatives.

✓ No history of adverse reactions to vaccines or medications.

✓ No history of allergies to medications and foods.

✓ Patients must have laboratory parameters (blood count, renal function (GFR), partial urine, fasting blood glucose, specific antigen and ACE.

✓ human chronic gonadotropin pregnancy test) negative no more than two weeks, serology VDRL, HBsAg, anti- VHC Y Elisa para VIH negatives.

- Active bleeding or uncontrolled active infection.

- Dx of HIV infection, viral hepatitis, tuberculosis or immunosuppressed patients.

- Pre-existing autoimmune disease.

- Psychiatric illness, cognitive disability (ability to understand information about the study) / social situation that would limit the fulfillment of the study.

- Person who have participated in previous clinical studies.

- Women in pregnancy and/or breastfeeding.

- Men and women of childbearing age who do not use a safe method of family planning (condom with spermicide, IUD, subdermal implants, oral and/or injectable contraceptives and Pomeroy).

    ✓ - Consumers of psychoactive substances.